DNA Aptamers for the Malignant Transformation Marker CD24

被引:7
|
作者
Fafinska, Joanna [1 ]
Czech, Andreas [1 ]
Sitz, Tobias [1 ]
Ignatova, Zoya [1 ]
Hahn, Ulrich [1 ]
机构
[1] Hamburg Univ, MIN Fac, Inst Biochem & Mol Biol, Chem Dept, Martin Luther King Pl 6, D-20146 Hamburg, Germany
关键词
CD24 DNA aptamers; cell-SELEX; diversity assay; cell surface glycoprotein; INDEPENDENT PROGNOSTIC MARKER; IN-VITRO SELECTION; MONOCLONAL-ANTIBODIES; PANCREATIC-CANCER; INITIATING CELLS; MOLECULE L1; EXPRESSION; IDENTIFICATION; GENE; PROGRESSION;
D O I
10.1089/nat.2018.0748
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cluster of differentiation 24 (CD24) is a cell surface glycoprotein, which is largely present on hematopoietic cells and many types of solid tumor cells. CD24 is known to be involved in a wide range of downstream signaling pathways and neural development, yet the underlying mechanisms are poorly understood. Moreover, its production correlates with poor cancer prognosis, and targeting of CD24 with different antibodies has been shown to inhibit disease progression. Nucleic acid aptamers are oligonucleotides that are selected from random DNA or RNA libraries for high affinity and specific binding to a certain target. Thus, they can be used as an alternative to antibodies. To gain an insight on CD24 role and its interaction partners, we performed several SELEX (systematic evolution of ligands by exponential enrichment) experiments to select CD24-specfiic DNA aptamers. We found that the cell-SELEX approach was the most useful and that using HT-29 cell line presenting CD24 along with CD24 knockdown HT-29 cells has selected six aptamers. For the selected aptamers, we determined dissociation constants in the nanomolar range (18-709nM) using flow cytometry. These aptamers can be applied as diagnostic tools to track cancer progression and bear a potential for therapeutic use for inhibiting signaling pathways that promote the metastatic process.
引用
收藏
页码:326 / 334
页数:9
相关论文
共 50 条
  • [1] Identification of CD24 as a marker for tumorigenesis of melanoma
    Tang, Ming-Rui
    Guo, Jia-Yan
    Wang, Di
    Xu, Nan
    ONCOTARGETS AND THERAPY, 2018, 11 : 3401 - 3406
  • [2] CD24 is a marker for human breast carcinoma
    Fogel, M
    Friederichs, J
    Zeller, Y
    Husar, M
    Smirnov, A
    Roitman, L
    Altevogt, P
    Sthoeger, ZM
    CANCER LETTERS, 1999, 143 (01) : 87 - 94
  • [3] CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma
    Pinato, David J.
    Nya, Paul
    Sharma, Rohini
    Mauri, Francesco A.
    JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (03) : 256 - 259
  • [4] CD24 enhances malignant features of glioblastoma
    Fukushima, Tsuyoshi
    Kawaguchi, Makiko
    Yamamoto, Koji
    Tanaka, Hiroyuki
    Kataoka, Hiroaki
    CANCER SCIENCE, 2018, 109 : 1353 - 1353
  • [5] Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development
    Elghetany, MT
    Patel, J
    AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (04) : 348 - 349
  • [6] CD24 expression is an independent prognostic marker in cholangiocarcinoma
    Agrawal, S.
    Kuvshmoff, B. W.
    Khoury, T.
    Yu, J.
    Javle, M. M.
    LeVea, C.
    Groth, J.
    Coignet, L. J.
    Gibbs, J. F.
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 57 - 57
  • [7] CD24 Expression is an Independent Prognostic Marker in Cholangiocarcinoma
    Shefali Agrawal
    Boris W. Kuvshinoff
    Thaer Khoury
    Jihnhee Yu
    Milind M. Javle
    Charles LeVea
    Jeff Groth
    Lionel J. Coignet
    John F. Gibbs
    Journal of Gastrointestinal Surgery, 2007, 11 : 445 - 451
  • [8] CD24 expression is an independent prognostic marker in cholangiocarcinoma
    Agrawal, Shefali
    Kuvshinoff, Boris W.
    Khoury, Thaer
    Yu, Jihnhee
    Javle, Milind M.
    LeVea, Charles
    Groth, Jeff
    Coignet, Lionel J.
    Gibbs, John F.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2007, 11 (04) : 445 - 451
  • [9] CD24
    Henniker, AJ
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2001, 15 (02): : 182 - 184
  • [10] CD24 expression is a new prognostic marker in breast cancer
    Kristiansen, G
    Winzer, KJ
    Mayordomo, E
    Bellach, J
    Schlüns, K
    Denkert, C
    Dahl, E
    Pilarsky, C
    Altevogt, P
    Guski, H
    Dietel, M
    CLINICAL CANCER RESEARCH, 2003, 9 (13) : 4906 - 4913